

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

UNIVERSITY OF MASSACHUSETTS and  
CARMEL LABORATORIES, LLC,

Plaintiffs,

v.

L'ORÉAL USA, INC.,

Defendant.

Case No. 17-cv-868-CFC-SRF

**NOTICE OF DEPOSITION PURSUANT TO RULE 30(b)(6)**

PLEASE TAKE NOTICE that, pursuant to Rule 30(b)(6) of the Federal Rules of Civil Procedure, on a date and at a location to be agreed upon by the Parties, counsel for the University of Massachusetts and Carmel Laboratories, LLC, will take the videotaped deposition(s) of the designated representative(s) of L'Oréal USA, Inc., best able to testify as to the matters set forth in Exhibit 1. L'Oréal USA, Inc., has a duty to designate one or more officers, directors, managing agents, or other persons with sufficient knowledge to testify fully regarding the topics listed in Exhibit 1. No later than ten business days prior to the deposition, L'Oréal USA, Inc., shall identify the person(s) who will testify on its behalf pursuant to this notice and the matter(s) about which each person will testify.

The deposition(s) will be taken before a Notary Public or some other officer authorized by law to administer oaths for use at trial. The above deposition(s) will be videotaped and will continue from day to day until completed.

DATED: February 7, 2020

Respectfully submitted,

FARNAN LLP

/s/ Brian E. Farnan

Brian E. Farnan (Bar No. 4089)  
Michael J. Farnan (Bar No. 5165)  
919 North Market Street, 12<sup>th</sup> Floor  
Wilmington, DE 19801  
Telephone: (302) 777-0300  
Facsimile: (302) 777-0301  
bfarnan@farnanlaw.com  
mfarnan@farnanlaw.com

Of Counsel:

William Christopher Carmody  
Tamar E. Lusztig  
Beatrice C. Franklin  
SUSMAN GODFREY L.L.P.  
1301 Avenue of the Americas, 32<sup>nd</sup> Floor  
New York, NY 10019  
Telephone: (212) 336-8330  
Facsimile: (212) 336-8340  
bcarmody@susmangodfrey.com  
tlusztig@susmangodfrey.com  
bfranklin@susmangodfrey.com  
Justin A. Nelson  
SUSMAN GODFREY L.L.P.  
1000 Louisiana Street, Suite 5100  
Houston, Texas 77002  
Telephone: (713) 651-9366  
Facsimile: (713) 654-6666  
jnelson@susmangodfrey.com

*Attorneys for University of Massachusetts  
and Carmel Laboratories, LLC*

Matthew B. Lowrie  
FOLEY & LARDNER LLP  
111 Huntington Avenue, Suite 2600  
Boston, MA 02199  
Telephone: (617) 342-4000  
Facsimile: (617) 342-4001

mlowrie@foley.com

*Attorneys for Carmel Laboratories, LLC*

COMMONWEALTH OF MASSACHUSETTS,

By its attorney,

MAURA HEALEY  
ATTORNEY GENERAL

By: William Christopher Carmody  
William Christopher Carmody  
Special Assistant Attorney General  
SUSMAN GODFREY L.L.P.  
1301 Avenue of the Americas, 32<sup>nd</sup> Floor  
New York, NY 10019  
Telephone: (212) 336-8330  
Facsimile: (212) 336-8340  
bcarmody@susmangodfrey.com

*Attorney for University of Massachusetts  
Medical School*

## **EXHIBIT 1**

### **Definitions**

1. The terms “Defendant,” “You,” “Your,” or “L’Oréal” shall refer to defendant L’Oréal USA, Inc., and shall include L’Oréal S.A. as well as L’Oréal USA Inc.’s parent, subsidiaries, affiliates, divisions, successors or assignees, and their respective officers, directors, employees, consultants, representatives, and agents.
2. The term “Document” or “Documents” is used in the broadest sense permitted by the Federal Rules of Civil Procedure and means the original (or any copy when originals are not available) and any drafts or non-identical copies thereof.
3. The terms “Asserted Patents” and “Patents-in-Suit” shall mean United States Patents No. 6,423,327 and 6,645,513.
4. The term “Accused Products” refers to the products listed in Exhibit A to Plaintiffs’ Disclosure of Asserted Claims and Initial Infringement Contentions, served on October 10, 2019, subject to any subsequent supplement or amendment
5. The terms “all” and “each” shall be construed as “and,” “each,” and “and/or.”
6. The term “any” should be understood in either its most or least inclusive sense as will bring within the scope of the topic all responses that might otherwise be construed to be out of its scope.
7. The term “including” shall mean including but not limited to.
8. The terms “relate,” “relating,” or “related” mean in any way, directly or indirectly, in whole or part, relating to, concerning, referring to, discussing, mentioning, regarding, pertaining to, describing, reflecting, containing, analyzing, studying, reporting on, commenting on, evidencing, constituting, setting forth, considering, recommending, modifying, amending, confirming, endorsing, representing, supporting, qualifying, terminating, revoking, refuting, undermining, canceling, contradicting or negating.
9. The terms “and” and “or” shall be construed disjunctively or conjunctively as necessary to bring within the scope of these topics all information which might otherwise be construed to be outside their scope.
10. The terms “sale,” “sales,” “sell” or “sold” shall include sales, licenses, leases, loans, consignments, distribution to resellers or others (including, but not limited to, to Your related and affiliated entities) and all other methods of product distribution whether direct or indirect, and whether the product is distributed singly or in combination with or as part of another product, and whether or not revenue was or will be received therefrom.

### Topics

1. How L'Oréal realizes, recognizes, and classifies revenues from the Accused Products, including a description of L'Oréal's methodology for characterizing revenue as U.S. or international for U.S. tax purposes.
2. L'Oréal's accounting practices pertaining to the Accused Products, including L'Oréal's methods of accounting for revenues, costs, profits, methods or depreciation, allocation of expenses, inventory measurements, profit allocation, losses, and assignments of debt.
3. L'Oréal's methods for valuing the Accused Products with respect to their contributions to good will, user retention, advertising revenue, collection of user data, and/or contribution to other revenue-generating products of L'Oréal.
4. L'Oréal's revenues, assigned costs, profit margins, and total profits for the Accused Products.
5. For the financial records and/or financial summary documents produced by L'Oréal in this litigation, the circumstances under which those records were generated, the accounting methods and practices employed in generating such records, the underlying data from which such records were generated, the explanation of any terms or legends in such records, and reconciliation of those figures to those disclosed in public filings, including the definitions and amounts of any deductions and allowances necessary for reconciliation.
6. License agreements, settlement agreements, and/or royalty agreements relating to the Accused Products or to L'Oréal's damages contentions that L'Oréal, or its affiliates or assigns, has entered into from 2005 to the present or that cover that period.
7. License agreements, settlement agreements, and/or royalty agreements relating to L'Oréal's use of adenosine in its products and/or otherwise relating to the Accused Products.
8. Any patents or proprietary technology owned or licensed by L'Oréal relating to adenosine.
9. From 2008 to the present, L'Oréal's evaluation of patents or other proprietary technology relating to the Accused Products, and L'Oréal's methods or practices for determining values or royalty rates for such technology.
10. L'Oréal's policies and practices concerning patent licensing, including any standard or preferred terms for license agreements and the process or practices by which L'Oréal determines the nature, scope, and terms of license agreements in which L'Oréal or its affiliates or assigns is a licensee.
11. L'Oréal's marketing and financial plans, market studies, reports, forecasts, surveys, strategies, and projections for the sale, use, or monetization of the Accused Products, including L'Oréal's media and advertising campaigns related to the Accused Products. This topic is limited to 2010 to the present.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.